New antibody shot could help babies beat HIV – trial launches
NCT ID NCT07655128
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether adding a lab-made antibody (ePGT121v1-LS) to standard HIV medication can help infants under one year old achieve better viral suppression. About 87 infants in South Africa will receive either the antibody or a placebo injection every 12 weeks for 48 weeks. Researchers will monitor safety, how the body processes the antibody, and whether it improves HIV control compared to standard treatment alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
broadly neutralizing antibody (bNAb) ePGT121v1-LS
What this could lead to
If it works, this could point toward a more effective way to control HIV in infants, potentially leading to better long-term viral suppression and health outcomes.
What could go wrong
This is an early-phase trial with a small number of infants, so results may not confirm safety or effectiveness. The antibody may not work as hoped, and there could be side effects from the injections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••